Pure Global
NCT06304571

A Study of HC006 in Subjects With Advanced Solid Tumors

A Phase I, Open-label, Dose-Escalation and Dose-expansion Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Efficacy of HC006 in Advanced Solid Tumor Subjects
HC Biopharma Inc.·Phase 1·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Advanced Solid Tumor
Drug/Device/Intervention
HC006
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
HC Biopharma Inc.
Location
Shanghai, China
Timeline & enrollment
Phase
Phase 1
Start date
Feb 27, 2024
End date
Jul 16, 2026
Enrollment
76 participants
Primary outcome

Incidence of Dose Limiting Toxicities(DLTs),Incidence of adverse events(AEs),Incidence of Serious adverse events(SAEs),Clinically Significant changes in safety assessments

Summary

The purpose of this study is to characterize the safety, tolerability, pharmacokinetics (PK),
 Immunogenicity and preliminary antitumor activity of HC006 in subjects with advanced solid
 tumor malignancies. This study is a first-in-human (FIH) study of HC006 in subjects with
 advanced solid tumors.

ICD-10 classifications
Carcinoma in situ, unspecifiedMalignant neoplasm: PrepuceMalignant neoplasm: Connective and soft tissue, unspecifiedMalignant neoplasm: ParametriumMalignant neoplasm of other connective and soft tissue
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06304571
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06304571 through Pure Global AI's free database. This Phase 1 trial is sponsored by HC Biopharma Inc. and is currently Recruiting. The study focuses on Advanced Solid Tumor. Target enrollment is 76 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.